Clinical Trials
17 trialsNCT02498613 2026-05-01
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03775486 2026-05-01
ORION
AstraZeneca
Phase 2 Active not recruiting
NCT02679963 2026-04-06
PIPSeN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT05568212 2025-12-01
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT05623319 2025-06-24
THOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT06419179 2025-05-20
GUIDANCE
University of Cologne
Phase 2 Enrolling by invitation
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT04538378 2025-01-27
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT05411679 2023-06-12
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Ellipses Pharma
Phase 2 Withdrawn
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT03531840 2021-04-09
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03009682 2021-02-18
SUKSES-B
Samsung Medical Center
Phase 2 Completed
NCT03428607 2021-02-18
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
Samsung Medical Center
Phase 2 Completed
NCT01788332 2018-10-26
PIN
Velindre NHS Trust
Phase 2 Unknown